FBRX
Forte Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 43 | +6 | 8.85M | $188.14M | +11 | −5 |
| Q1 2026 | 38 | +5 | 7.04M | $182.49M | +8 | −3 |
| Q4 2025 | 33 | +1 | 5.99M | $163.53M | +3 | −2 |
| Q3 2025 | 11 | +5 | 1.51M | $22.69M | +5 | n/a |
| Q2 2025 | 5 | +1 | 990.17K | $12.80M | +1 | n/a |
| Q1 2025 | 2 | +1 | 74.69K | $579,605 | +1 | n/a |
| Q4 2024 | 1 | 0 | 16.88K | $383,375 | n/a | n/a |
| Q3 2024 | 1 | -3 | 14.27K | $79,930 | n/a | −3 |
| Q2 2024 | 4 | n/a | 528.60K | $283,908 | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 486.92K | n/a | $6.30M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Adage Capital Partners ✦ | 333.33K | New | $4.31M | 0.0% | New | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 72.12K | +393.8% | $932,460 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 64.11K | +6.7% | $829,054 | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | BlackRock ✦ (passive) | 33.70K | n/a | $435,676 | 0.0% | n/c | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $4.31M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 40.00K shares, $1,036 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.